October 19, 2021 07:23 AM EDT

Covid-19 roundup: FDA to give OK for mix-and-match booster shots — report; WHO group leads campaign to acquire antiviral drugs for $10

Josh Sullivan

The mix-and-match school of thought is picking up a victory as the FDA reportedly plans to allow Americans to receive a different Covid-19 booster than …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: FDA to give OK for mix-and-match booster shots — report; WHO group leads campaign to acquire antiviral drugs for $10

Josh Sullivan

Sign up to read this article for free.

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Outlook's shares crash as wet AMD drug flunks Phase 3 test

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Novartis to cut 139 jobs in NJ as part of commercial refocus

Covid-19 roundup: FDA to give OK for mix-and-match boost­er shots — re­port; WHO group leads cam­paign to ac­quire an­tivi­ral drugs for $10

Josh Sullivan

Sign up to read this article for free.

more like this

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Out­look's shares crash as wet AMD drug flunks Phase 3 test

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Covid-19 roundup: FDA to give OK for mix-and-match booster shots — report; WHO group leads campaign to acquire antiviral drugs for $10

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Outlook's shares crash as wet AMD drug flunks Phase 3 test

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Novartis to cut 139 jobs in NJ as part of commercial refocus